Analyst Valuation and EPS Growth for Agile Therapeutics (NASDAQ:AGRX)

0
773

Earnings results for Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics, Inc. is estimated to report earnings on 10/26/2020. The upcoming earnings date is derived from an algorithm based on a company’s historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 3 analysts’ forecasts, the consensus EPS forecast for the quarter is $-0.18. The reported EPS for the same quarter last year was $-0.08.

Agile Therapeutics last announced its quarterly earnings data on August 11th, 2020. The specialty pharmaceutical company reported ($0.12) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.14) by $0.02. Agile Therapeutics has generated ($0.38) earnings per share over the last year. Agile Therapeutics has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, October 26th, 2020 based off prior year’s report dates.

Analyst Opinion on Agile Therapeutics (NASDAQ:AGRX)

5 Wall Street analysts have issued ratings and price targets for Agile Therapeutics in the last 12 months. Their average twelve-month price target is $7.75, predicting that the stock has a possible upside of 159.20%. The high price target for AGRX is $9.00 and the low price target for AGRX is $6.00. There are currently 1 hold rating and 4 buy ratings for the stock, resulting in a consensus rating of “Buy.”

Agile Therapeutics has received a consensus rating of Buy. The company’s average rating score is 2.80, and is based on 4 buy ratings, 1 hold rating, and no sell ratings. According to analysts’ consensus price target of $7.75, Agile Therapeutics has a forecasted upside of 159.2% from its current price of $2.99. Agile Therapeutics has only been the subject of 3 research reports in the past 90 days.

Dividend Strength: Agile Therapeutics (NASDAQ:AGRX)

Agile Therapeutics does not currently pay a dividend. Agile Therapeutics does not have a long track record of dividend growth.

Insiders buying/selling: Agile Therapeutics (NASDAQ:AGRX)

In the past three months, Agile Therapeutics insiders have bought more of their company’s stock than they have sold. Specifically, they have bought $25,650.00 in company stock and sold $0.00 in company stock. Only 8.50% of the stock of Agile Therapeutics is held by insiders. 44.10% of the stock of Agile Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Earnings and Valuation of Agile Therapeutics (NASDAQ:AGRX

Earnings for Agile Therapeutics are expected to grow in the coming year, from ($0.64) to ($0.60) per share. The P/E ratio of Agile Therapeutics is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. The P/E ratio of Agile Therapeutics is -7.48, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Agile Therapeutics has a P/B Ratio of 3.88. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

More latest stories: here